Perrigo 10-Q Details $351.6M Nine-Month Loss, $332.6M Impairments and $275M-$375M Infant Formula Hit
PRGO sits 78% above its 52-week low of $9.225.
Summary
Perrigo's Q3 10-Q shows a $27.5M quarterly loss and $351.6M nine-month loss after $332.6M of goodwill impairments, with sales down 5.2% and a $275M-$375M loss expected on the pending Infant Formula sale.
Key Events · Earnings and Guidance · PRGO
-
Q3 Swings to $27.5M Loss
Net sales fell 5.2% to $988.6M from $1,043.3M; diluted EPS was $(0.20) versus $0.05 a year ago, and the nine-month net loss reached $351.6M.
-
$332.6M Goodwill Impairments
Q1 charges hit Women's Health ($77.4M), Infant Formula ($66.3M) and Oral Care ($187.2M) after the segment reorganization; accumulated goodwill impairments now total $2,659.9M.
-
Infant Formula Sale Loss Guided
The MeridianMade deal is worth up to $175M — $40M cash at closing plus up to $135M contingent through 2030 — and Perrigo expects a $275.0M-$375.0M held-for-sale loss in Q4 2026.
-
Debt Cut by $761.8M
Nine-month long-term debt payments of $761.8M included a $335.0M revolver repayment from Dermacosmetics proceeds; cash stood at $436.6M versus $531.6M at year-end 2025.
Analysis · PRGO · Life Sciences
The 10-Q fills in the numbers behind this morning's loss and guidance cut. Nine-month net loss reached $351.6M, driven by $332.6M of goodwill impairments booked in Q1 when the new segment structure was set up — Women's Health, Infant Formula and Oral Care were written down. Third-quarter sales fell 5.2% to $988.6M and gross margin dropped 370 basis points to 32.4% on planned under-absorption in Infant Formula and softer Self Care volumes. The bigger forward item is the Infant Formula sale to MeridianMade: only $40M is cash at closing, and the company expects to book a $275.0M-$375.0M loss on held-for-sale remeasurement in Q4 2026. Debt paydown of $761.8M in the nine months and a $335.0M revolver repayment from Dermacosmetics proceeds leave $436.6M of cash, but Women's Health and Skin Health goodwill now sit on thin margins, so another impairment is possible if performance slips.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRGO was trading at $16.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $9.23 to $20.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.